Abstract B077: Subtype-specific signaling dynamics during treatment in non-responding breast cancer patients in the neoadjuvant I-SPY2 TRIAL: are there clues on how to overcome resistance?
Denise M. Wolf, Laura van ‘t Veer, Lajos Pusztai(Yale University), Paula R. Pohlmann(The University of Texas MD Anderson Cancer Center), Lamorna Brown Swigart(University of California, San Francisco), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Douglas Yee(University of Minnesota Medical Center), Amrita Basu(University of Calcutta), Rosa I. Gallagher(George Mason University), Christina Yau(Hospital Authority), Amy S. Clark(Abramson Center for Jewish Life), Mark Jesus M. Magbanua(University of California, San Francisco), Jane Perlmutter(Gemini Computers (United States)), Laura J. Esserman(University of California, San Francisco), Rosalyn W. Sayaman(University of California, San Francisco), Gillian L. Hirst(University of California, San Francisco), Hope S. Rugo(City of Hope), Julia D. Wulfkhule(George Mason University), Michael J. Campbell(University of California, San Francisco), Angela DeMichele(University of Pennsylvania)
Cited by 0
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k